<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825550</url>
  </required_header>
  <id_info>
    <org_study_id>B-BR-104-046</org_study_id>
    <nct_id>NCT02825550</nct_id>
  </id_info>
  <brief_title>Taiwan ACE Beads for Hepatoma Embolization Therapy</brief_title>
  <official_title>Radiopaque Microsphere (Hydrophilic Series) for Hepatoma Embolization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Industrial Technology Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng Kung University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Program for Biopharmaceuticals, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Radiopaque Microsphere
      (T-ACE Beads) interventional therapy for patients with liver cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the safety and tolerability of Taiwan ACE Beads used for
      chemoembolization for the treatment of unresectable hepatocellular carcinoma.

      The investigators will study the overall response rates of lesions with Taiwan ACE Beads. The
      procedure is similar with conventional TACE (transcatheter arterial chemoembolization). At
      the target vessels, radiologists will inject lipiodol with doxorubicin first, then Taiwan ACE
      Beads instead of Gelfoam or PVA (polyvinyl alcohol). The end point of injection is also
      similar with conventional TACE.

      Determine the complication rates, progression free survival (PFS) and overall survival (OS)
      following Taiwan ACE Beads embolization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Survival (Safety)</measure>
    <time_frame>An average of 12 weeks.</time_frame>
    <description>Survival rate was evaluated since treatment day until the date of death or final observation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Response (Efficacy)</measure>
    <time_frame>Before treatment, one month and three month after T-ACE using CT scan and MRI</time_frame>
    <description>mRECIST criteria was used to evaluate tumor response in patients with hepatoma who received Taiwan ACE beads (T-ACE) microspheres embolization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Level of AFP</measure>
    <time_frame>Baseline serum AFP levels compared with one or three months of serum levels of AFP after Taiwan ACE Beads procedure</time_frame>
    <description>Serum Level of AFP [Time Frame: Baseline serum AFP levels (168±383) compared with one or three months of serum levels of AFP (144±256) after Taiwan ACE Beads procedure]</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Cancer of Liver</condition>
  <arm_group>
    <arm_group_label>Hepatoma treated using Taiwan ACE Beads</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The use of Taiwan ACE Beads (T-ACE) microspheres embolization as a treatment for patients with hepatoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taiwan ACE Beads</intervention_name>
    <description>Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.</description>
    <arm_group_label>Hepatoma treated using Taiwan ACE Beads</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must meet all of the following inclusion criteria in order to be entered into the
        study:

        A. Both genders of patients age 18 or older.

        B. Patients diagnosed of liver cancer (MUST meet at least ONE of the following criteria:)

          1. Diagnosed via tumor biopsy by Pathologists, and confirmed by on-service physician.

          2. High risk patients (Viral hepatitis B or C or cirrhotics) with typical liver cancer
             image appeared on more than two radiographic examinations (Ultrasound, MRI, CT scan or
             Angiography).

          3. High risk patients (Viral hepatitis B or C cirrhotics) with evidence of enlarging
             image of liver cancer via more than two follow-up records.

        C. In intermediate stage by BCLC staging, tumor size between 3 to 6 centimeters, with liver
        function at Child-Pugh class&lt;9, and is either difficult to accept an operation or reluctant
        to accept any operation.

        D. Disease can be treated by transarterial chemoembolization, and can be evaluated by
        Ultrasound, Magnetic resonance imaging (MRI), or computed tomography (CT).

        E. Performance status ECOG 2 or less. Patient has a life expectancy of at least 3 months.

        Exclusion Criteria:

        If patients meet any of the following criteria they may not be entered into the study:

        A. major branch of portal vein has been invaded already; extrahepatic metastasis or the the
        other malignant tumors.

        B. Evidences of decompensation: Total Bilirubin&gt;2, PT prolong&gt;3 seconds, AST &gt; 500U/L, ALT&gt;
        500U/L, Child-Pugh class≧9, refractory ascites, active bleeding, hepatic encephalopathy,
        and severe infection.

        C. Tumor size (diameter) larger than 6 centimeters or smaller than 3 centimeters.

        D. Cr&gt;2.0 mg/dL and eGFR&lt;50%.

        E. Allergic to iodine or other injections.

        F. Other main organ failure (Heart, Lung, or Kidney)

        G. WBC&lt;3000, ANC&lt;1500.

        H. Performance status ECOG of 3 or more.

        I. Unable to follow-up by ultrasound or CT scan.

        J. Unwilling to sign a written informed consent form.

        K. Pregnant women and breath feeding women.

        L. Patients whose blood vessel are too difficult to do Taiwan ACE Beads procedure.

        M. Prominent AV shunt.

        N. Severe atherosclerosis.

        O. Vasospasm or possible major vascular injury.

        P. Arteriovenous shunt patients, diameter larger than the size of microsphere available.

        Q. Collateral vascular exists and may endanger non-targeted area during arterial
        chemoembolization.

        R. Contraindications for doxorubicin.

        S. Number of tumors more than 3 and locate at different lobes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi-Zhang Lin</last_name>
    <role>Study Director</role>
    <affiliation>Department of Internal Medicine, National Cheng Kung University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Liu YS, Lin XZ, Tsai HM, Tsai HW, Chen GC, Chen SF, Kang JW, Chou CM, Chen CY. Development of biodegradable radiopaque microsphere for arterial embolization-a pig study. World J Radiol. 2015 Aug 28;7(8):212-9. doi: 10.4329/wjr.v7.i8.212.</citation>
    <PMID>26339465</PMID>
  </reference>
  <reference>
    <citation>Chen CY, Liu HS, Lin XZ. Hydrodynamics-based gene delivery to the liver by bile duct injection of plasmid DNA--the impact of lasting biliary obstruction and injection volume. Hepatogastroenterology. 2005 Jan-Feb;52(61):25-8.</citation>
    <PMID>15782986</PMID>
  </reference>
  <reference>
    <citation>Luo TY, Shih YH, Chen CY, Tang IC, Wu YL, Kung HC, Lin WJ, Lin XZ. Evaluating the potential of (188)Re-ECD/lipiodol as a therapeutic radiopharmaceutical by intratumoral injection for hepatoma treatment. Cancer Biother Radiopharm. 2009 Oct;24(5):535-41. doi: 10.1089/cbr.2008.0603.</citation>
    <PMID>19877883</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 2, 2016</study_first_submitted>
  <study_first_submitted_qc>July 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <results_first_submitted>January 24, 2017</results_first_submitted>
  <results_first_submitted_qc>August 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2018</results_first_posted>
  <last_update_submitted>August 6, 2018</last_update_submitted>
  <last_update_submitted_qc>August 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatoma</keyword>
  <keyword>Transcatheter Arterial chemo-embolization</keyword>
  <keyword>Microsphere</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment started in April, 2016. The location was all taken place in National Cheng Kung University Hospital. Patients who met inclusion criteria were recruited.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hepatoma Patients Treated With T-ACE Beads</title>
          <description>In the Hepatoma Embolization Therapy, the catheter was placed to the appropriate position in tumor-supplying artery. Lipiodol containing doxorubicin were firstly injected, followed by the injection of our T-ACE beads-H series microspheres. The follow-up blood tests and adverse events were conducted afterwards. CT scan or MRI would be scheduled at the first and the third months to evaluate the change of tumor size.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hepatoma Treated Using Taiwan ACE Beads</title>
          <description>Clinical information of T-ACE beads H-series: Gender Male/Female 7/5, Age 71±8. The initial number of participants in the study was 13. However, one patient's blood test did not meet the standard before the operation, which led to his/her withdrawal from the clinical trial. Consequently, the total number of participants analyzed was 12.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients Survival (Safety)</title>
        <description>Survival rate was evaluated since treatment day until the date of death or final observation.</description>
        <time_frame>An average of 12 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hepatoma Treated Using Taiwan ACE Beads</title>
            <description>Hepatoma patients received Taiwan ACE Beads (T-ACE) microspheres embolization to treat the tumors.
Taiwan ACE Beads: The procedure is similar with conventional TACE. Radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
Survival rate was evaluated since beginning of treatment until date of death or final observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Survival (Safety)</title>
          <description>Survival rate was evaluated since treatment day until the date of death or final observation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response (Efficacy)</title>
        <description>mRECIST criteria was used to evaluate tumor response in patients with hepatoma who received Taiwan ACE beads (T-ACE) microspheres embolization.</description>
        <time_frame>Before treatment, one month and three month after T-ACE using CT scan and MRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hepatoma Patients Treated With T-ACE Beads</title>
            <description>We have 7 male and 5 female patients eligible in this study, HBV 4+1, HCV5+1, non-HBV and non-HCV 2, mean age 71± 8. Two patient received treatment at the first time. The other 10 patients received RFA 13 times, and TACE 23 times, and surgery 2 times. The response of the target lesions are: CR 3 PR 4 SD 3 PD 2 (for target lesions), and CR 2 PR 3 SD 3 PD 4 (for the overall response). Liver function, serological ALT(35±24) had mild elevation on the second day (61±47), but all return to baseline (40±20). AFP decreased from 168± 382 to 156± 264. [Conclusion] Our T-ACE Beads are safe and has some effects in treating hepatoma patients.For further clinical trials, loading appropriate chemotherapeutic agents to our microspheres for TACE is needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response (Efficacy)</title>
          <description>mRECIST criteria was used to evaluate tumor response in patients with hepatoma who received Taiwan ACE beads (T-ACE) microspheres embolization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Target Lesions</title>
              <category_list>
                <category>
                  <title>Complete Remission (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease (SD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Response</title>
              <category_list>
                <category>
                  <title>Complete Remission (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease (SD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Level of AFP</title>
        <description>Serum Level of AFP [Time Frame: Baseline serum AFP levels (168±383) compared with one or three months of serum levels of AFP (144±256) after Taiwan ACE Beads procedure]</description>
        <time_frame>Baseline serum AFP levels compared with one or three months of serum levels of AFP after Taiwan ACE Beads procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hepatoma Treated Using Taiwan ACE Beads</title>
            <description>Hepatoma patients received Taiwan ACE Beads (T-ACE) microspheres embolization to treat the tumors.
Taiwan ACE Beads: The procedure is similar with conventional TACE. Radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Level of AFP</title>
          <description>Serum Level of AFP [Time Frame: Baseline serum AFP levels (168±383) compared with one or three months of serum levels of AFP (144±256) after Taiwan ACE Beads procedure]</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline serum AFP levels</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" spread="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>one or three months of serum levels of AFP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adverse Event</title>
          <description>There was no adverse event reported in this trial.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Case number : only 12 patients completed trial.
Tumor size limited to 3-6 cm only.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Xi-Zhang Lin</name_or_title>
      <organization>Department of Internal Medicine, National Cheng Kung University</organization>
      <phone>886-6-2353535 ext 3624/5603</phone>
      <email>linxz@mail.ncku.edu.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

